BeiGene (SHA:688235, HKG:6160) expects 2025 revenue to range between 35.2 billion yuan and 38.1 billion yuan on the back of Brukinsa's strong market position in the US and continued expansion in Europe and other key global markets.

Gross margin is projected to be in the mid-range of 80% to 90%, according to a Friday filing with the Shanghai bourse.

Meanwhile, research and development, sales, and administrative expenses are expected to range between 29.5 billion yuan and 31.9 billion yuan.

Shares of the drug company jumped 7% in recent trade on the Shanghai bourse.